首页> 美国卫生研究院文献>The Journal of Biological Chemistry >Transcriptional Repression of Tumor Suppressor CDC73 Encoding an RNA Polymerase II Interactor by Wilms Tumor 1 Protein (WT1) Promotes Cell Proliferation
【2h】

Transcriptional Repression of Tumor Suppressor CDC73 Encoding an RNA Polymerase II Interactor by Wilms Tumor 1 Protein (WT1) Promotes Cell Proliferation

机译:Wilms肿瘤1蛋白(WT1)编码RNA聚合酶II相互作用的抑癌基因CDC73的转录抑制。促进细胞增殖。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Wilms tumor 1 gene (WT1) can either repress or induce the expression of genes. Inconsistent with its tumor suppressor role, elevated WT1 levels have been observed in leukemia and solid tumors. WT1 has also been suggested to act as an oncogene by inducing the expression of MYC and BCL-2. However, these are only the correlational studies, and no functional study has been performed to date. Consistent with its tumor suppressor role, CDC73 binds to RNA polymerase II as part of a PAF1 transcriptional regulatory complex and causes transcriptional repression of oncogenes MYC and CCND1. It also represses β-catenin-mediated transcription. Based on the reduced level of CDC73 in oral squamous cell carcinoma (OSCC) samples in the absence of loss-of-heterozygosity, promoter methylation, and mutations, we speculated that an inhibitory transcription factor is regulating its expression. The bioinformatics analysis predicted WT1 as an inhibitory transcription factor to regulate the CDC73 level. Our results showed that overexpression of WT1 decreased CDC73 levels and promoted proliferation of OSCC cells. ChIP and EMSA results demonstrated binding of WT1 to the CDC73 promoter. The 5-azacytidine treatment of OSCC cells led to an up-regulation of WT1 with a concomitant down-regulation of CDC73, further suggesting regulation of CDC73 by WT1. Exogenous CDC73 attenuated the protumorigenic activity of WT1 by apoptosis induction. An inverse correlation between expression levels of CDC73 and WT1 was observed in OSCC samples. These observations indicated that WT1 functions as an oncogene by repressing the expression of CDC73 in OSCC. We suggest that targeting WT1 could be a therapeutic strategy for cancer, including OSCC.
机译:Wilms肿瘤1基因(WT1)可以阻遏或诱导基因表达。与它的肿瘤抑制作用不一致,在白血病和实体瘤中观察到WT1水平升高。 WT1还被认为通过诱导MYC和BCL-2的表达而作为癌基因。但是,这些只是相关研究,迄今为止尚未进行功能研究。与它的肿瘤抑制作用一致,CDC73结合RNA聚合酶II作为PAF1转录调控复合物的一部分,并引起癌基因MYC和CCND1的转录抑制。它还抑制β-连环蛋白介导的转录。基于在缺乏杂合性缺失,启动子甲基化和突变的情况下口腔鳞状细胞癌(OSCC)样品中CDC73的水平降低,我们推测抑制性转录因子正在调节其表达。生物信息学分析预测WT1是调节CDC73水平的抑制性转录因子。我们的结果表明,WT1的过表达降低CDC73水平并促进OSCC细胞增殖。 ChIP和EMSA结果表明WT1与CDC73启动子结合。 OSCC细胞的5-氮杂胞苷处理导致WT1的上调,同时伴随CDC73的下调,进一步提示WT1对CDC73的调节。外源CDC73通过凋亡诱导减弱了WT1的致瘤活性。在OSCC样品中观察到CDC73和WT1的表达水平呈负相关。这些观察结果表明,WT1通过抑制OSCC中CDC73的表达而充当癌基因。我们建议靶向WT1可能是包括OSCC在内的癌症治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号